82 results
To determine the accuracy of the URIKA urinary bladder sensor in measuring the distance between the anterior - and posterior wall of the bladder and to determine the range in bladder diameters at which the child should be alarmed to void.
- To evaluate the bladder-preservation rate after chemoradiation - To evaluate the toxicity and complications of treatment with induction chemotherapy followed by ePLND and chemoradiation
Primary Objective: Is the detection chance of the bladder influenced by the angle in which the ultrasound sensor is fixated? Secondary Objective Can the URIKA Bladder Monitor (UBM) be used to predict the point where the BladderScan reaches the…
Is the day alarm a usefull tool for parents and children to gain more insight in there urine incontinence. By getting a signal at the moment of wetting, parents and children can be trained in a more efficient way to gain more control of their…
In this study, the aim is to perform a clinical evaluation of the NovioMini in children during behavioural bladder training to examine the performance of the NovioMini as a full-bladder-based notification system during natural bladder filling.
The aim is to determine the immediate effect of sacral neuromodulation on urodynamic measurements.
To evaluate BlueWind Medical RENOVATM System safety and performance in OAB patients for extended FU period of 36 months.
Objective: The principal objective is To evaluate the long-term safety and maintenance of efficacy of BOTOX® (200 U) injected into the detrusor for the treatment of urinary incontinence caused by neurogenic detrusor overactivity in patients who have…
To evaluate the safety and efficacy of solifenacin succinate suspension once daily in children and adolescents with OAB.
Evaluation of the accuracy of the sentinel node procedure in bladder cancer patients.
The objective of the study is to analyse flow pattern, especially individual variation, and the extend of voiding symtoms in young females and
Increasing diuresis rate in patients with Overactive Bladder symptom complex as a possible treatment
1) Is the difference in diuresis between patients and volunteers caused by a dept in water household in patients and if so can we increase the diuresis in patients by correcting this?2) Can we influence the pattern of bladder sensations by…
The objective of the study is to measure the extend of voiding symptoms and bother of the urinary tract in young females and to analyse flow patterns and post void residual.
The purpose of this trial is to demonstrate the superior efficacy of pudendal neuromodulation in treating patients with neurogenic overactive bladder, who have failed conservative treatment, in a randomized cross-over trial.Symptoms of urinary…
MAIN: To study the influence of increasing diuresis rate on sensation development in patients with OAB complaints. SECONDARY:To study changes in sensory complaints induced by increasing diuresis rate in patients with OAB complaints. If the…
The primary objectives are the following:- To assess the safety profile and determine the Optimal Biological Dose (OBD) or Maximum Tolerated Dose (MTD), whichever occurs first, of intravesically administered TMX-101. The secondary objectives are the…
1. Monitoring of cellular (T-cel) specifc immune response in bladder and bloodsamples after intravesical BCG- therapy. 2. Monitoring and comparing T-cell responses after BCG therapy in patients with clinical BCG-related complications to the T-…
What is the most reliable way, defined as the lowest percentage rate of urines which are contaminated, to collect urine in pregnant women to asses bacteriuria? Comparison of three different methods of collection: midstream morning urine, midstream…
This study is a phase I trial. Primary objective is to evaluate the safety of combined radiotherapy with Panitumumab in bladder preservation in invasive bladder cancer. Secondary objectives are to investigate the efficacy of combined radiotherapy…
The primary objective of this study is to provide an updated pharmacokinetic profile of orally administered nitrofurantoin in women aged 55 to 75 years.